Filing Analysis
eXoZymes Inc. closed a unit offering on June 30, 2026, consisting of common stock and warrants for $18.00 per unit. The offering includes highly dilutive 'Warrant Reset' provisions that could trigger a massive reduction in exercise price to $0.001 if future financing occurs at less than $8.99.
🚩 Red Flags
- Extremely aggressive 'Warrant Reset' provision: If the company sells equity below $8.99 before June 5, 2027, the warrant exercise price resets to $0.001.
- Potential for massive dilution due to the reset mechanism and high number of warrants issued.
- The offering is relatively small ($640k gross), suggesting limited runway or urgent need for capital.
📋 Key Facts
- Closed an offering of 35,555 units on June 30, 2026.
- Each unit contains 2 shares of common stock and 1 warrant (totaling 71,110 shares and 35,555 warrants).
- Unit price is $18.00; the implied share price component is $8.99 per share.
- Warrants have an exercise price of $11.24, exercisable starting June 5, 2027.
- Gross proceeds were $639,990 before commissions and expenses.
- MDB Capital received a warrant to purchase 10,666 shares at $11.24 per share.
Exozymes Inc. announced it has been awarded a $2 million NIH grant to advance cannabinoid analogs for drug discovery purposes.
📋 Key Facts
- Award amount: $2 Million
- Grantor: National Institutes of Health (NIH)
- Purpose: Advancing cannabinoid analogs for drug discovery
- Announcement date: June 24, 2026
eXoZymes Inc. completed a firm commitment underwritten offering of common stock and warrants, including the partial exercise of an over-allotment option by the underwriter MDB Capital. The company raised approximately $5.95 million in gross proceeds to fund R&D and commercialization of N-trans-caffeoyltyramine (NCT).
🚩 Red Flags
- Issuance of warrants alongside common stock creates potential future dilution for existing shareholders.
📋 Key Facts
- Gross proceeds from the offering totaled approximately $5.95 million.
- The offering consisted of units priced at $18.00, each containing two shares of common stock and one warrant.
- Initial offering included 592,270 shares and 296,135 warrants.
- On June 17, 2026, MDB Capital exercised a portion of the over-allotment option for 34,440 units (68,880 shares and 34,440 warrants).
- Proceeds are earmarked for development and commercialization of NCT, additional product opportunities, R&D, and general working capital.
eXoZymes Inc. entered into a firm commitment underwritten offering on June 5, 2026, to sell units consisting of two shares of common stock and one warrant. The offering is expected to raise approximately $5.33 million in gross proceeds, potentially increasing to $6.13 million if the over-allotment option is exercised.
🚩 Red Flags
- Aggressive Warrant Reset: The exercise price of warrants resets to $0.001 if the company sells securities at a price below $8.99 before the first anniversary of the agreement, which is a highly dilutive 'death spiral' characteristic.
- Significant offering expenses relative to net proceeds ($253,000 in expenses on ~$5.3M gross).
📋 Key Facts
- Offering consists of 592,270 shares and 292,135 warrants sold as units (2 shares : 1 warrant).
- Offering price per unit is $18.00.
- Expected gross proceeds are $5,330,430, with estimated commissions of $373,130 and expenses of $253,000.
- Over-allotment option allows MDB Capital to purchase an additional 88,840 shares and 44,420 warrants.
- Warrants have an exercise price of $11.24 and a five-year term, exercisable after one year.
- Proceeds are earmarked for NCT business development, R&D, working capital, and capital expenditures.
- Expected closing date is on or about June 9, 2026.
eXoZymes Inc. has filed an investor presentation in anticipation of a proposed public offering of its securities. The presentation is intended for potential underwriters and offering participants to facilitate the capital raise.
🚩 Red Flags
- Potential for significant shareholder dilution resulting from the proposed public offering.
- Micro-cap companies frequently conduct offerings at a discount to market price to attract underwriters.
📋 Key Facts
- The filing was made on May 7, 2026, under Item 8.01 (Other Events).
- The company is preparing for a proposed public offering of securities.
- An investor presentation (Exhibit 99.1) was attached to the filing for use in the offering process.
- eXoZymes Inc. is an emerging growth company listed on the Nasdaq Capital Market under the ticker EXOZ.
Exozymes Inc. filed an 8-K to disclose an investor presentation being shared with potential underwriters for a proposed securities offering. This indicates the company is actively seeking to raise capital in the near term.
🚩 Red Flags
- Imminent share dilution likely resulting from the 'proposed offering of securities'.
- The company is a micro-cap registrant which often faces high costs of capital and significant dilution during offerings.
📋 Key Facts
- The filing was made on April 10, 2026, under Item 8.01 (Other Events).
- The company is providing an Investor Presentation to potential underwriters and offering participants.
- The registrant is an emerging growth company listed on the Nasdaq Capital Market.
- The presentation is included as Exhibit 99.1.
Exozymes Inc. filed an updated investor presentation on March 30, 2026, specifically focusing on its NCTx business unit. The presentation was disclosed as an exhibit to the 8-K filing under Item 8.01.
📋 Key Facts
- The filing occurred on March 31, 2026, with an event date of March 30, 2026.
- The primary purpose of the filing is to provide an updated Investor Presentation for the company's NCTx business.
- The presentation is included as Exhibit 99.1.
- The company is an emerging growth company listed on the Nasdaq Capital Market under the ticker EXOZ.
Exozymes Inc. announced the commercial readiness of its initial NCT pilot run via a press release dated January 29, 2026.
📋 Key Facts
- The company is advancing toward commercial readiness for its initial NCT pilot run.
- The announcement was made in conjunction with a press release dated January 29, 2026.
- The filing was signed by Fouad Nawaz, Vice President of Finance.
Exozymes Inc. filed an 8-K to announce a press release regarding the scaling up of NCT production using their proprietary exozymes. The filing is a routine disclosure of operational progress.
📋 Key Facts
- Company announced scale-up of NCT (Neutrallase/Enzyme) production on December 11, 2025.
- The announcement was made via a press release attached as Exhibit 99.1.
- The filing is categorized under Item 8.01 (Other Events).
eXoZymes Inc. filed an 8-K to provide an updated Investor Presentation specifically related to its NCTx business as of November 13, 2025.
📋 Key Facts
- The filing is an update to the company's investor presentation.
- The presentation is specifically in connection with the 'NCTx business'.
- Date of report: November 13, 2025.
eXoZymes Inc. filed an 8-K to provide an updated Investor Presentation as of September 30, 2025. The filing contains no material changes to operations or financial structure.
📋 Key Facts
- The company released an updated Investor Presentation dated September 30, 2025.
- Filing date is October 3, 2025.
- Reported under Item 8.01 (Other Events).
eXoZymes Inc. held its 2025 Annual Meeting of Stockholders on July 25, 2025. Shareholders approved the election of six directors, a performance equity plan, and the appointment of RBSM LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on July 25, 2025.
- Six nominees elected to serve until the 2026 annual meeting: Christopher A. Marlett, Anthony DiGiandomenico, James U. Bowie, James J. Lalonde, Lon E. Bell, and Edgardo Rayo.
- Shareholders approved the 2025 Performance Equity Plan (Proposal 4).
- RBSM LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2025 (Proposal 5).
- Shareholders determined that advisory votes on executive compensation will occur every three years (Proposal 3).
- Quorum reached with 4,779,773 votes representing 56.98% of shares entitled to vote.
eXoZymes Inc. filed an 8-K to provide an updated Investor Presentation as of July 7, 2025.
📋 Key Facts
- The filing was triggered by Item 8.01 (Other Events).
- An updated Investor Presentation dated July 7, 2025, was attached to the report.
- The company is an emerging growth company.
eXoZymes Inc. has been selected as the key industrial partner for the NSF-funded Meta-PURE initiative, a three-year project led by Georgia Institute of Technology. The company will receive approximately $3 million of the total $9.2 million award to develop cell-free ATP-generating modules and production modules for high-value compounds like santalene.
📋 Key Facts
- Selected as key industrial partner in the Meta-PURE initiative under the NSF CFIRE program.
- Project is led by The Georgia Institute of Technology.
- eXoZymes to receive ~$3 million from a total project award of $9.2 million.
- Project duration: 3 years, commencing July 1, 2025.
- Technical focus: Developing a cell-free ATP-generating 'power plant' module and a production module for santalene (high-value fragrance/pharmaceutical compound).
eXoZymes Inc. announced an increase in compensation for CEO Michael Heltzen, including a base salary adjustment, a one-time bonus, and a new stock option grant.
🚩 Red Flags
- Significant cash outlay ($250k bonus) for a micro-cap company may be scrutinized relative to current liquidity/burn rate (though not explicitly stated in this filing).
📋 Key Facts
- Effective Date of Report: June 17, 2025
- CEO Michael Heltzen's base salary increased to an annualized rate of $450,000.00.
- Grant of 235,817 stock options with an exercise price of $12.40 per share.
- Options vest over a four-year period in equal quarterly installments starting July 1, 2025.
- One-time bonus of $250,000.00 awarded to the CEO.
ExoZymes Inc. filed an 8-K to announce an upcoming investor call regarding the company's fourth quarter and full year 2024 financial and operational updates.
📋 Key Facts
- The company announced an investor call on April 2, 2025.
- The purpose of the call is to provide updates for Q4 and Full Year 2024.
- The filing includes a press release (Exhibit 99.1) detailing these updates.
eXoZymes Inc. announced the appointment of Damien Perriman as the new Chief Commercial Officer (CCO) on April 2, 2025.
📋 Key Facts
- Damien Perriman has been hired as the Chief Commercial Officer (CCO).
- The announcement was made on April 2, 2025.
- The company is an emerging growth company.
eXoZymes Inc. announced a significant leadership overhaul on February 17, 2025, involving the resignation of its President and Chairman of the Board, Mohammad Hayat.
🚩 Red Flags
- Simultaneous departure of both the President and the Chairman of the Board, indicating significant leadership instability.
- Sudden exit of a key executive (President) often signals internal friction or strategic shifts in micro-cap companies.
📋 Key Facts
- Mohammad Hayat resigned from the Board and all positions (President and Chairman) effective February 17, 2025.
- Edgardo Rayo was appointed to the Board to fill the vacancy created by Mr. Hayat's resignation; no compensation arrangement is currently in place for this role.
- Christopher A. Marlett has been appointed as the new Chairman of the Board.
Invizyne Technologies Inc. has officially changed its corporate name to 'eXoZymes Inc.' as of February 10, 2025. This filing serves as a formal notification of the amendment to its articles of incorporation regarding the name change.
📋 Key Facts
- Effective date of name change: February 10, 2025
- Former name: Invizyne Technologies Inc.
- New name: eXoZymes Inc.
- Ticker symbol remains EXOZ on the Nasdaq Capital Market
Invizyne Technologies Inc. successfully consummated its Initial Public Offering (IPO) on November 14, 2024, raising approximately $14.3 million in net proceeds. The offering included the issuance of 1,875,000 shares at $8.00 per share and a concurrent private placement of warrants.
🚩 Red Flags
- Potential dilution from underwriter warrants (150,000 shares) and private placement warrants (93,750 shares).
- Conversion of existing SAFEs into common stock results in immediate share count increase.
- Underwriter has a 45-day option to purchase additional shares, which could further dilute current holders.
📋 Key Facts
- Consummated IPO of 1,875,000 common shares at $8.00 per share on November 14, 2024.
- Net proceeds from the IPO totaled $14,321,686 after underwriting discounts and expenses.
- Underwriter (MDB Capital) granted a 45-day option to purchase up to 281,250 additional shares.
- Issued warrants to the Underwriter for up to 150,000 shares at an exercise price of $10.00 per share (5-year term).
- Completed a concurrent private offering of 93,750 warrants at $0.125 per warrant with an $8.00 exercise price.
- Converted 125,001 shares via SAFEs issued on July 3, 2023, to MDB Capital Holdings LLC and Paul Opgenorth.
- New ticker symbol 'IZTC' began trading on Nasdaq Capital Market on November 13, 2024.